九安醫療(002432.SZ)：美國子公司收到紐約州和馬薩諸塞州就iHealth試劑盒的採購訂單
格隆匯1月12日丨九安醫療(002432.SZ)公佈，公司子公司iHealth Labs.Inc(簡稱“美國子公司”)收到的紐約州和馬薩諸塞州發來的下述就iHealth新冠抗原家用自測OTC試劑盒(簡稱“iHealth試劑盒”)的訂單，生效時間為收到訂單當日(當地時間)；與美國紐約州衞生部簽署的iHealth試劑盒銷售合同由雙方於當地時間2022年1月10日生效。
美國子公司於當地時間2021年12月21日收到了美國紐約州衞生部(NewYork State Department of Health)發來的兩份分別由美國紐約州衞生部和紐約州非盈利組織 Health Research Incorporated 就 iHealth試劑盒的採購訂單(簡稱“紐約州訂單”)，訂單金額分別為2508萬美元(含運費)和4023萬美元(含運費)，合計訂單金額為6531萬美元(含運費)，約合人民幣4.16億元(按照2022年1月12日美元兑人民幣匯率中間價1美元=6.3658元人民幣計算)。
此外，美國子公司和美國紐約州衞生部於當地時間2022年1月10日簽訂了《銷售合同》(簡稱“紐約州合同”)，向美國紐約州衞生部銷售iHealth試劑盒產品，合同價税合計金額為1.2億美元(含運費)，約合人民幣7.64億元(按照2022年1月12日美元兑人民幣匯率中間價1美元=6.3658元人民幣計算)。
截止本公吿日，美國子公司與紐約州衞生部的訂單及合同金額累計達人民幣11.796億元(含運費、税)，已超過公司2020年度經審計主營業務收入的50%(人民幣10.04億元)。
美國子公司於美國當地時間2021年12月3日至2022年1月5日期間獲得了美國馬薩諸塞聯邦及衞生與公眾服務部執行辦公室(The Commonwealth of Massachusetts and Executive office of Health and Human Services)的採購訂單(簡稱“馬薩諸塞州訂單”)，公司美國子公司向美國馬薩諸塞聯邦及衞生與公眾服務部執行辦公室銷售iHealth試劑盒，合同價税合計金額為1.48億美元(含運費)，約合人民幣9.44億元(按照2022年1月12日美元兑人民幣匯率中間價計算)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
